Wew!

With the theoretical genome in hand, Ostrov and colleagues began testing their design in living cells. They divided the recoded genome into 87 segments, each about 50 kb long—containing an average of 40 genes—and handed the design off to biotech companies to synthesize the DNA. The researchers then began integrating each segment into a separate strain of E. coli and deleting the corresponding wild-type DNA to check for viability.
“In principle you could do this whole-genome synthesis in vitro and then transplant the genome,” said Church. Instead, his team developed a pipeline to obtain real-time feedback from living cells: “Assembly occurs with the motor running,” he explained.
In their paper, the researchers review the results of this validation for 55 of the 87 genome segments, covering 63 percent of the recoded genome.The initial computational design for the recoded genome wasn’t quite perfect: 13 essential genes had fatal errors that killed the E. coli when the wild-type DNA segment was deleted.
“We anticipated that there would be so-called synonymous or silent positions that aren’t really synonymous or silent, where we’d overlap with regulatory elements or secondary structures,” said Church. To resolve these errors, the researchers pinpointed each individual problematic codon and tested replacement—but still synonymous—sequences.
“It is a bit surprising to see how plastic the genome could be,” Patrick Cai, a synthetic biologist at the University of Edinburgh who was not involved with the work, wrote in an email to The Scientist. “It is also very exciting to see [that] technologies such as computational design, de novo synthesis and assembly, as well as a range of phenotyping assays, are now mature to support genome refactoring at this scale.”
The team must still finish validating the rest of the synthesized DNA segments and then combine them in vivo. “This is, of course, an exciting paper with clear advances,” said Patrick O’Donoghue, a biochemist at Western University in Canada who was not involved with the work. O’Donoghue pointed out two key issues that represent future hurdles for the field: first, preventing the replacement codons from mutating back to the original genome state; second, if the codons are someday reintroduced with matching tRNAs to insert noncanonical amino acids, preventing the normal near-cognate tRNAs from translating them as well. “The strain that they’re working towards will be useful, but there will clearly be some technological challenges,” he added.
archive.is/1SaLp

...

...

...

...

...

...

...

...

...

...

...

Checked

...

...

Continue this story.

But does this new strain make the test subjects weaker to other diseases?

this is how I am Legend started

...

Congrats you learned how to green text. Go fuck yourself

who are you quoting?

...

...

...

heh